JP2017508465A - 組換えイスファハンウイルスベクター - Google Patents

組換えイスファハンウイルスベクター Download PDF

Info

Publication number
JP2017508465A
JP2017508465A JP2016555578A JP2016555578A JP2017508465A JP 2017508465 A JP2017508465 A JP 2017508465A JP 2016555578 A JP2016555578 A JP 2016555578A JP 2016555578 A JP2016555578 A JP 2016555578A JP 2017508465 A JP2017508465 A JP 2017508465A
Authority
JP
Japan
Prior art keywords
protein gene
virus
isfv
protein
risfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016555578A
Other languages
English (en)
Japanese (ja)
Inventor
ファルーク ネイサー
ファルーク ネイサー
デメトリアス マタスソフ
デメトリアス マタスソフ
ロディオン ブイ. ゴルチャコフ
ロディオン ブイ. ゴルチャコフ
ステファン ハム
ステファン ハム
レベッカ ノヴァク
レベッカ ノヴァク
ロバート エル. セイモア
ロバート エル. セイモア
ジョン エイチ. エルドリッジ
ジョン エイチ. エルドリッジ
ロバート ビー. テシュ
ロバート ビー. テシュ
デビッド ケイ. クラーク
デビッド ケイ. クラーク
テレサ イー. ラザム
テレサ イー. ラザム
スコット ウィーバー
スコット ウィーバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2017508465A publication Critical patent/JP2017508465A/ja
Priority to JP2020015937A priority Critical patent/JP7454393B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016555578A 2014-03-01 2015-02-27 組換えイスファハンウイルスベクター Pending JP2017508465A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020015937A JP7454393B2 (ja) 2014-03-01 2020-02-03 組換えイスファハンウイルスベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946734P 2014-03-01 2014-03-01
US61/946,734 2014-03-01
PCT/US2015/018156 WO2015134332A2 (en) 2014-03-01 2015-02-27 Recombinant isfahan viral vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020015937A Division JP7454393B2 (ja) 2014-03-01 2020-02-03 組換えイスファハンウイルスベクター

Publications (1)

Publication Number Publication Date
JP2017508465A true JP2017508465A (ja) 2017-03-30

Family

ID=54055975

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016555578A Pending JP2017508465A (ja) 2014-03-01 2015-02-27 組換えイスファハンウイルスベクター
JP2020015937A Active JP7454393B2 (ja) 2014-03-01 2020-02-03 組換えイスファハンウイルスベクター
JP2022095401A Pending JP2022126723A (ja) 2014-03-01 2022-06-14 組換えイスファハンウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020015937A Active JP7454393B2 (ja) 2014-03-01 2020-02-03 組換えイスファハンウイルスベクター
JP2022095401A Pending JP2022126723A (ja) 2014-03-01 2022-06-14 組換えイスファハンウイルスベクター

Country Status (14)

Country Link
US (1) US9932564B2 (cg-RX-API-DMAC10.html)
EP (1) EP3113795B1 (cg-RX-API-DMAC10.html)
JP (3) JP2017508465A (cg-RX-API-DMAC10.html)
KR (1) KR102416194B1 (cg-RX-API-DMAC10.html)
CN (1) CN106794240A (cg-RX-API-DMAC10.html)
AU (1) AU2015225553B2 (cg-RX-API-DMAC10.html)
CA (1) CA2941261A1 (cg-RX-API-DMAC10.html)
DK (1) DK3113795T3 (cg-RX-API-DMAC10.html)
ES (1) ES2749381T3 (cg-RX-API-DMAC10.html)
IL (2) IL247545B (cg-RX-API-DMAC10.html)
MX (1) MX369776B (cg-RX-API-DMAC10.html)
SG (1) SG11201607287XA (cg-RX-API-DMAC10.html)
WO (1) WO2015134332A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201606036B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525781A (ja) * 2021-07-14 2024-07-12 上海栄瑞医薬科技有限公司 腫瘍溶解性ウイルス及びその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
EP3681523A4 (en) * 2017-09-15 2021-12-29 The Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
EP3823654B1 (en) * 2018-07-17 2024-02-14 Yale University Methods for treatment of cancer using chikungunya-vsv chimeric virus
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034625A1 (en) * 1995-05-04 1996-11-07 Yale University Recombinant vesiculoviruses and their uses
JP2007535918A (ja) * 2004-04-09 2007-12-13 ワイス 水疱性口内炎ウイルスの相乗的弱毒化、そのベクター及びその免疫原性組成物
JP2010503660A (ja) * 2006-09-15 2010-02-04 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
JP2010535495A (ja) * 2007-08-03 2010-11-25 インスティチュート・パスツール レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2011516040A (ja) * 2008-03-14 2011-05-26 サノフィ パスツール バイオロジクス カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
US20120014990A1 (en) * 2009-03-16 2012-01-19 Brian Lichty Vaccination methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE468859T1 (de) 2003-03-26 2010-06-15 Wyeth Llc Immunogene zusammensetzung und verfahren
CN101087886B (zh) * 2004-04-09 2013-07-17 惠氏公司 疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒
KR101723900B1 (ko) * 2009-06-08 2017-04-07 더 유니버시티 오브 웨스트 온타리오 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형
PT3351636T (pt) * 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
US20130095556A1 (en) * 2011-09-21 2013-04-18 International Aids Vaccine Initiative Novel vesicular stomatitis virus and virus rescue system

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034625A1 (en) * 1995-05-04 1996-11-07 Yale University Recombinant vesiculoviruses and their uses
US6168943B1 (en) * 1995-05-04 2001-01-02 Yale University Methods for making modified recombinant vesiculoviruses
JP2007535918A (ja) * 2004-04-09 2007-12-13 ワイス 水疱性口内炎ウイルスの相乗的弱毒化、そのベクター及びその免疫原性組成物
JP2010503660A (ja) * 2006-09-15 2010-02-04 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
JP2010535495A (ja) * 2007-08-03 2010-11-25 インスティチュート・パスツール レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2011516040A (ja) * 2008-03-14 2011-05-26 サノフィ パスツール バイオロジクス カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
US20120014990A1 (en) * 2009-03-16 2012-01-19 Brian Lichty Vaccination methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH VIROL, vol. 150, JPN6018043103, 2005, pages 671 - 680, ISSN: 0004127163 *
PLOS ONE, vol. Volume 8, Issue 6, JPN6018043101, 2013, pages 67123, ISSN: 0004127164 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525781A (ja) * 2021-07-14 2024-07-12 上海栄瑞医薬科技有限公司 腫瘍溶解性ウイルス及びその使用
JP7857683B2 (ja) 2021-07-14 2026-05-13 上海栄瑞医薬科技有限公司 腫瘍溶解性ウイルス及びその使用

Also Published As

Publication number Publication date
CN106794240A (zh) 2017-05-31
DK3113795T3 (da) 2019-10-21
KR20160135740A (ko) 2016-11-28
SG11201607287XA (en) 2016-09-29
KR102416194B1 (ko) 2022-07-04
CA2941261A1 (en) 2015-09-11
IL247545A0 (en) 2016-11-30
EP3113795A2 (en) 2017-01-11
IL290258A (en) 2022-04-01
MX2016011300A (es) 2017-05-08
ES2749381T3 (es) 2020-03-20
EP3113795B1 (en) 2019-07-10
MX369776B (es) 2019-11-21
IL247545B (en) 2022-03-01
AU2015225553A1 (en) 2016-09-15
US9932564B2 (en) 2018-04-03
JP2020078318A (ja) 2020-05-28
EP3113795A4 (en) 2017-07-26
WO2015134332A2 (en) 2015-09-11
JP7454393B2 (ja) 2024-03-22
US20170067027A1 (en) 2017-03-09
ZA201606036B (en) 2020-02-26
AU2015225553B2 (en) 2020-02-27
JP2022126723A (ja) 2022-08-30
WO2015134332A3 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
JP7454393B2 (ja) 組換えイスファハンウイルスベクター
KR101790187B1 (ko) 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터
US8647638B2 (en) Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
US20190175720A1 (en) Zika virus vaccine and combination vaccine
JP2017538417A (ja) レンチウイルスベクターに基づく日本脳炎免疫原性組成物
BR112014015390B1 (pt) Proteína de matriz modificada (m) de um vírus da estomatite vesicular, vírus da estomatite vesicular recombinante, vacina compreendendo o mesmo, kit e uso de uma vacina
WO2014093602A1 (en) Compositions and methods for treating and preventing hepatitis c virus infection
US20230321219A1 (en) SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES
CN1981043B (zh) 用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用
US20160279229A9 (en) Viral Vaccine Vectors
CN108743934B (zh) 利用重组水泡性口炎病毒构建预防猪流行性腹泻病毒疫苗
AU2011269729A1 (en) Constrained immunogenic compositions and uses therefor
US9566329B2 (en) Live, attenuated rubella vector to express vaccine antigens
CN101087886A (zh) 疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒
ES2410593T3 (es) Ácidos nucleicos y polipéptidos de lisavirus quiméricos
HK1233173A1 (en) Recombinant isfahan viral vectors
HK1233173B (en) Recombinant isfahan viral vectors
EP4574168A1 (en) Prime-boost immunization against influenza
US9181306B2 (en) Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
JP2024503482A (ja) 複製可能アデノウイルス4型sars-cov-2ワクチンおよびそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191003